Kirill Osipov commented on the recent invalidation of yet another patent of Russian generic producer «Nativa»

«Pharmaceutical Bulletin» – one of the largest professional magazines devoted to Russian pharma – published an article on the recent invalidation of yet another patent of «Nativa». «Nativa» is a Russian generic producer, infamous for its involvement in numerous patent infringement cases with the largest originator makers. Nativa’s patent, rendered invalid in the end of January, was for invention claimed to be dependent on the substance patented by Bristol-Myers Squibb and used in the production of Sprycel.

The Head of Legal Department of ARS-Patent Kirill Osipov provided his comments to «Pharmaceutical Bulletin» on the case and the acute problem of dependent inventions in general.

The full article is available here.

Make an enquiry

Latest News

More about our presence in IP rankings


Last week IP STARS published results of their extensive annual research on IP firms with the focus on patent practice. ARS-Patent is pleased to remain...

Read more
ARS-Patent remains listed in prestigious rankings


ARS-Patent was again listed among the leading IP filers in Russia: Chambers Europe included our firm in the third Band in IP filing category for 2018....

Read more

View all our News


Meet ARS-Patent at INTA 2019


On May 18-22, 2019, ARS-Patent will attend the annual meeting of International Trademark Association (INTA), which will take place in Boston, Massachu...

Read more
Meet with us at AIPLA 2018 Annual Meeting


Mikhail Khmara, Managing Partner of ARS-Patent and the Head of Patent Department, will be attending AIPLA 2018 Annual Meeting on October 25-27 in Was...

Read more

See all Events

Back top